Go to deals
Healthcare

Clínica Las Condes has completed a successful bond voluntary call option

Clínica Las Condes has completed a bond voluntary call option with the goal of reducing financial debt and interest expenses.

Based in Santiago, Chile, Clínica Las Condes is one of the largest private hospitals in the country. It initiated its operations in 1982, with a focus in high complexity medicine. Its services include inpatient medical, surgical intensive care units, intermediate, adult, pediatric, neonatal, surgical wards, post-recovery operative, clinical laboratories, radiology, CT magnetic resonance imaging, radiation therapy, PET-CT, nuclear medicine, ultrasound, dialysis and other services that include outpatient procedures.

Oaklins’ team in Chile acted as financial advisor to Clínica Las Condes.

Talk to the deal team

Sebastián Cereceda

Partner
Santiago, Chile
Oaklins LarrainVial

Related deals

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Healthcare

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Learn more
Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more